Skip to main navigation Skip to search Skip to main content

In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers

  • Qing-Bin Lu*
  • , Qin-Rong Zhang
  • , Ning Ou
  • , Chun-Rong Wang
  • , Jenny Warrington
  • *Corresponding author for this work

Research output: Journal Publications and Reviews › RGC 21 - Publication in refereed journal › peer-review

4 Downloads (CityUHK Scholars)

Abstract

Based on a molecular-mechanism-based anticancer drug discovery program enabled by an innovative femtomedicine approach, we have found a previously unknown class of non-platinum-based halogenated molecules (called FMD compounds) as potent antitumor agents for effective treatment of cancers. Here, we present in vitro and in vivo studies of the compounds for targeted chemotherapy of cervical, breast, ovarian, and lung cancers. Our results show that these FMD agents led to DNA damage, cell cycle arrest in the S phase, and apoptosis in cancer cells. We also observed that such a FMD compound caused an increase of reduced glutathione (GSH, an endogenous antioxidant) levels in human normal cells, while it largely depleted GSH in cancer cells. We correspondingly found that these FMD agents exhibited no or little toxicity toward normal cells/tissues, while causing significant cytotoxicity against cancer cells, as well as suppression and delay in tumor growth in mouse xenograft models of cervical, ovarian, breast and lung cancers. These compounds are therefore a previously undiscovered class of potent antitumor agents that can be translated into clinical trials for natural targeted chemotherapy of multiple cancers. © 2015.
Original languageEnglish
Pages (from-to)544-553
JournaleBioMedicine
Volume2
Issue number6
DOIs
Publication statusPublished - 1 Jun 2015
Externally publishedYes

Bibliographical note

Publication details (e.g. title, author(s), publication statuses and dates) are captured on an “AS IS” and “AS AVAILABLE” basis at the time of record harvesting from the data source. Suggestions for further amendments or supplementary information can be sent to [email protected].

Funding

This work was supported in part by the Canadian Institutes of Health Research (a grant to Q.B.L, #105218, and a New Investigator Award to Q.B.L), the Ontario Ministry of Research and Innovation (an Early Researcher Award to Q.B.L, #112621), and Natural Science and Engineering Research Council of Canada (NSERC, a grant to Q.B.L, #111333). No other funding sources have been provided in the writing of this manuscript or the decision to submit if for publication.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Keywords

  • Antitumor agents
  • Femtomedicine
  • Non-platinum-based compounds
  • Reductive DNA damage
  • Targeted chemotherapy

Publisher's Copyright Statement

  • This full text is made available under CC-BY-NC-ND 4.0. https://creativecommons.org/licenses/by-nc-nd/4.0/

Fingerprint

Dive into the research topics of 'In Vitro and In Vivo Studies of Non-Platinum-Based Halogenated Compounds as Potent Antitumor Agents for Natural Targeted Chemotherapy of Cancers'. Together they form a unique fingerprint.

Cite this